Who is affected by this change?

This affects Independence Blue Cross Hematology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 29, 2026.

Back to dashboard

CommercialAdministrativeLow impact

08.02.09b, Valoctocogene roxaparvovec-rvox (ROCTAVIAN™)

Independence Blue Cross·Hematology, Oncology·Pharmacy

Effective date

Apr 29, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a reissue of the existing policy for Valoctocogene roxaparvovec-rvox (ROCTAVIAN™), a gene therapy treatment. The policy is being reposted with an effective date of April 29, 2026, but no specific changes to coverage or billing requirements are detailed in the available content.

Action Required

Action needed

By April 29, 2026: Review the full policy document at the provided URL to understand any updates to coverage criteria, prior authorization requirements, or billing procedures for Valoctocogene roxaparvovec-rvox (ROCTAVIAN™). Update billing procedures and prior authorization workflows as specified in the complete policy text.

Related policy hubs

Independence Blue Cross policies Hematology Oncology